NPPA revises ceiling prices of 21 scheduled drugs and retail prices of 21 formulations

PSM News /

Mumbai, September 2016

The National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices of 21 scheduled formulations of Schedule-I under Drugs (Prices Control) Amendment Order, 2016 and retail price of 21 formulations under DPCO, 2013 through a Notification/order dated 15.9.2016.

 

Name of the scheduled formulations are paracetamol oral liquid, cefadroxil tablet, cefazolin powder for injection, kanamycin powder for injection, cyclosporin capsule, primaquine tablet, methotrexate tablet, levodopa + carbidopa tablet, hydrochlorothiazide tablet, carbamazepine tablet, sodium valproate injection, enoxaparin injection, cholecalciferol (vitamin D3) capsule, cholecalciferol (vitamin D3) tablet and levetiracetam oral liquid.

 

Retail price of scheduled formulations are formoterol fumarate + budesonide respules (budamate neb 0.5mg), formoterol fumarate + budesonide respules (budamate neb 1mg), atorvastatin + choline fenofibrate DR capsule, diclofenac capsule (IER-75), metoprolol + olmesartan tablet (Olkem Beta 25) olmesartan +metoprolol tablet (Olkem Beta 50), rosuvastatin + aspirin capsule (Zyrova ASP 150), tolperisone HCl + diclofenac sodium tablet (Tolkem-D), glimepiride + metformin HCl tablet (Glucoryl M3 Forte), glimepiride + metformin tablet (Glucoryl M3), amoxycillin + clavulanic acid tablet (Pencalv 1000), cefixime trihydrate+ ofloxacin tablet (Jetex OF), teneligliptin+ metformin HCl ER tablet (Megagliptin MF Forte), teneligliptin + metformin HCl SR tablet (Dynaglipt M Forte), povidone iodine+ ornidazole ointment (Lupidine - OZ), glimepiride tablet (Glucoryl 3mg), clotrimazole lotion (Triben), teneligliptin + metformin HCl  ER tablet, teneligliptin + metformin HCl SR tablet (Dynaglipt-M), paracetamol+caffeine+ phenylephrine+diphenhydramine tablet (Kolq – C).

 

Retail price is applicable only to the individual manufacturers/marketeers i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes/rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

 

The concerned manufacturers of said formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

 

In case the retail price of any of the formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

 

Consequent to the issue of retail price of the formulations as specified in this notification, the price order(s) if any, issued for concerned manufacturer/marketeer prior to said date of notification, stand(s) superseded, the NPPA said in the notification. Pharmabiz